University of New Haven

Digital Commons @ New Haven
Department of Forensic Science Publications

Forensic Science

2016

Screening of Exosomal MicroRNAs From
Colorectal Cancer Cells
Cillian Clancy
National University of Ireland, Galway

Sonja Khan
National University of Ireland Galway

Claire L. Glynn
University of New Haven, cglynn@newhaven.edu

Emma Holian
National University of Ireland, Galway

Peter Dockery
National University of Ireland, Galway
See next page for additional authors

Follow this and additional works at: http://digitalcommons.newhaven.edu/forensicscience-facpubs
Part of the Forensic Science and Technology Commons, Gastroenterology Commons, Genetics
and Genomics Commons, and the Oncology Commons
Publisher Citation
Clancy, Cillian, Sonja Khan, Claire L. Glynn, Emma Holian, Peter Dockery, Pierce Lalor, James AL Brown, Myles R. Joyce, Michael J.
Kerin, and Roisin M. Dwyer. "Screening of exosomal microRNAs from colorectal cancer cells." Cancer Biomarkers Preprint (2016):
1-9.

Comments
This is the authors' accepted version of the article published in Cancer Biomarkers. The final publication is available at IOS Press through
http://dx.doi.org/10.3233/CBM-160659 .

Authors

Cillian Clancy, Sonja Khan, Claire L. Glynn, Emma Holian, Peter Dockery, Pierce Lalor, James A.L. Brown,
Myles Joyce, Michael J. Kerin, and Roisin M. Dwyer

This article is available at Digital Commons @ New Haven: http://digitalcommons.newhaven.edu/forensicscience-facpubs/24

Title: Screening of Exosomal MicroRNAs from Colorectal Cancer Cells

Authors: Cillian Clancy 1, Sonja Khan 1, Claire L Glynn 1, Emma Holian 2, Peter Dockery 3,
Pierce Lalor 3, James A.L Brown 1, Myles R Joyce 1, 4, Michael J Kerin 1, Roisin M Dwyer 1.

Institutions:
Discipline of Surgery, Lambe Institute for Translational Research, National University of
Ireland Galway, Galway, Ireland 1,
School of Mathematics, Statistics and Applied Mathematics, National University of Ireland
Galway, Galway, Ireland 2,
Discipline of Anatomy, National University of Ireland Galway, Galway, Ireland 3,
Department of Colorectal Surgery, Galway University Hospital, Galway, Ireland 4

Corresponding Author:
Roisin M Dwyer
Discipline of Surgery, Lambe Institute for Translational Research, Galway, Ireland.
Email: roisin.dwyer@nuigalway.ie

1

ABSTRACT
Background: Cells release extracellular membrane vesicles including microvesicles known
as exosomes. Exosomes contain microRNAs (miRNAs) however the full range within
colorectal cancer cell secreted exosomes is unknown.
Objective: To identify the full range of exosome encapsulated miRNAs secreted from 2
colorectal cancer cell lines and to investigate engineering of exosomes over-expressing
miRNAs.
Methods: Exosomes were isolated from HCT-116 and HT-29 cell lines. RNA was extracted
from exosomes and microRNA array performed. Cells were engineered to express miR379(HCT-116-379) or a non-targeting control (HCT-116-NTC) and functional effects were
determined. Exosomes secreted by engineered cells were transferred to recipient cells and the
impact examined.
Results: Microvesicles 40-100nm in size secreted by cell lines were visualised and confirmed
to express exosomal protein CD63. HT-29 exosomes contained 409 miRNAs, HCT-116
exosomes contained 393, and 338 were common to exosomes from both cell lines. Selected
targets were validated. HCT-116-379 cells showed decreased proliferation (12-15% decrease,
p < 0.001) and decreased migration (32-86% decrease, p < 0.001) compared to controls.
HCT-116-379 exosomes were enriched for miR-379. Confocal microscopy visualised transfer
of HCT-116-379 exosomes to recipient cells.
Conclusions: Colorectal cancer cells secrete a large number of miRNAs within exosomes.
miR-379 decreases cell proliferation and migration, and miR-379 enriched exosomes can be
engineered.

Key words: exosomes, microRNAs, colorectal cancer
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Abbreviations: HCT-116-379; HCT-116 colorectal cancer cells transduced with a miR-379
over-expresing lentiviral vector, HCT-116-NTC; HCT-116 colorectal cancer cells transduced
with a non-targeting control lentiviral vector, HCT-116-WT; non transduced, wild-type HCT116 colorectal cancer cells, CRC – Colorectal Cancer, PBS – phosphate buffered saline
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INTRODUCTION
Cancer cells are capable of promoting pro-tumorigenic features such as angiogenesis through
paracrine signalling which can potentially promote metastases [1]. In addition to release of
soluble proteins, multiple cell types including colorectal cancer cells have been shown to
release a variety of extracellular membrane vesicles including microvesicles known as
exosomes. Exosomes are lipid vesicles with a diameter of 40-100nm which are highly stable,
facilitating collection from various body fluids as well as cell culture media [2]. They are
known to contain lipids, DNA and RNA and have recently been recognised as vehicles
capable of facilitating intercellular communication [3]. Emerging evidence indicates that
exosomes may play a role in a range of biological processes through transfer of their contents
from donor cells to recipient cells [4]. In cancer, exosomes also play a significant role with
evidence showing a pro-tumorigenic effect associated with the transfer of protein content [5].
One of the most exciting aspects of exosomes involvement in cancer is that they have
recently been found to contain miRNAs [6].

miRNAs are a class of small non-coding RNA molecules 19-25 nucleotides in length.
miRNAs regulate gene expression at a post transcriptional level leading to the inhibition of
mRNA translation or mRNA degradation [7]. Functional studies have shown miRNAs to
participate in almost every cellular process including apoptosis, proliferation and
differentiation [7, 8]. Some miRNAs are dysregulated in the tissues and circulation of CRC
patients making them promising as biomarkers [8, 9]. Recent studies, however, have reported
a number of miRNAs believed to be released by colorectal tumours as circulating markers of
disease are expressed by red blood cells and may be present in the plasma and serum
secondary to haemolysis [10]. Tumour derived exosomal miRNAs may provide a more
specific miRNA signature advancing the potential of early detection and individualised
treatments [11, 12].
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Recent studies have shown exosomes are capable of delivering chemotherapeutic agents in
vitro and can deliver anti-tumour miRNAs to breast cancer cells and prostate cancer cells
when injected systemically in vivo or directly into tumours [13-15]. Identification of potent
tumour suppressor miRNAs in CRC is useful for development of therapeutics in this regard.
miR-379 has previously been identified as a tumour suppressor in breast cancer [16]. A
genome wide analysis of miRNAs imprinted on the 14q32.31 locus including miR-379
reveals downregulation of these miRNAs in human cancers indicating this entire miRNA
cluster is a locus of tumour-suppressors [17]. These data, taken in conjunction with previous
studies showing compelling evidence that miR-379 is a tumour suppressor in breast cancer,
indicate miR-379 is an ideal candidate for further investigation in CRC. This study aimed to
firstly identify the full range of miRNAs packaged into exosomes and secreted by two CRC
cell lines with different phenotypical characteristics. The effect of miR-379 in CRC cells and
its potential to be transferred to recipient cells in exosomes was also examined.
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METHODS
Cell Lines and Culture Conditions
HCT-116 and HT-29 CRC cells were purchased from the American Type Culture Collection
(Manassas, VA, USA). Cell lines were last authenticated in May 2014 using DNA
fingerprinting. Cells were cultured in McCoys-5A media supplemented with 10% fetal
bovine serum (FBS) and 100U/ml penicillin/ 100 µg streptomycin (P/S). Cells were
incubated at 370C and 5% CO2.

Isolation of CRC Cell Secreted Exosomes
To prepare exosome-free media, exosomes were removed from FBS. FBS was centrifuged at
300 x g for 10 minutes followed by 2000 x g for 10 minutes to remove cellular debris. The
supernatant was then passed through a 0.2µm sterile filter. Exosomes were separated from the
supernatant by ultracentrifugation at 110,000 x g at 4°C for 70 minutes. After
ultracentrifugation the exosome free FBS supernatant was collected.

For exosome isolation, 2 x 106 cells were seeded into T-175 flasks containing 17 mLs of preprepared exosome free culture medium and cultured for 48 hours. A process of differential
centrifugation, passage through a microfilter and ultra-centrifugation was performed to
isolate exosomes [6]. In detail, following 48 hours incubation the media containing exosomes
secreted by cells was harvested. The cells remaining in the T-175 cm2 flask were then
trypsinised, counted and stored. A falcon containing cell conditioned media with exosomes
was placed into a centrifuge and spun at 300 x g for 10 minutes at 4 oC. The media was then
carefully collected from the falcon using a pipette leaving 1-2 mL remaining at the bottom
which contains cellular debris. Collected media was then transferred to a new falcon. This
underwent centrifugation at 2000 x g for 10 minutes at 4 oC. It was carefully collected from
the falcon using a pipette leaving 1-2 mL remaining at the bottom, passed through a 0.2 µm
6

sterile filter and collected in a new 50 mL falcon. A primary fixative was added at this point
prior to ultracentrifugation to maintain exosome morphology if exosomes were being isolated
for visualisation with Transmission Electron Microscopy (TEM). The media containing
exosomes was then transferred to an ultracentrifugation tube taking care to avoid any bubble
formation. A Sorvall 100SE ultracentrifuge was used with a Ti70 fixed angle rotor. The
following settings are used on the ultracentrifuge: spinning time was set for 1 hour and 10
minutes, temperature was set at 4 oC, acceleration was set at 9, deceleration at 1 and speed
was set at 100,000 x g. The ultracentrifugation tubes were carefully removed from the rotor
following the spin and the supernatant collected from the tubes using a disposable pipette.
The supernatant represents the cell conditioned media from which exosomes have been
removed. The exosome pellet was collected by pipetting 60 µL of PBS up and down the area
marked where the exosome pellet forms in the ultracentrifugation tube. Alternatively if
exosomes were harvested for Western Blot analysis, protein lysis buffer was used to resuspend the exosome pellet.

Transmission Electron Microscopy
HCT-116 and HT-29 exosomes were isolated as previously described. A primary fixative
(2% Glutaraldehyde, 2% Paraformaldehyde in a 0.1M Sodium Cacodylate/HCL buffer at a
pH of 7.2) was added to exosome containing media prior to the final ultracentrifugation step.
Exosomes were re-suspended in 50µL of PBS and treated with a secondary fixative (1%
Osmium Tetroxide). The resultant exosome pellet was subsequently dehydrated with graded
alcohol and then incubated in resin in a 65°C oven. The resin block was trimmed using an
ultramicrotome to sections of 80-100nm thickness (Reichert-Jung Ultracut E). Slices were
loaded onto a copper grid and stained with 1.5% aqueous uranyl acetate followed by lead
citrate. Viewing was performed with a Hitcachi H7000 Transmission Electron Microscope.
7

Western Blotting
HCT-116 and HT-29 secreted exosomes were collected as previously described. After
ultracentrifugation, exosomes were re-suspended in Triton-X lysis buffer [150mM NaCl, 20
mM HEPES, 2 mM EDTA, 1% Triton-X100, 2mM Sodium Orthovanadate, 10mM Sodium
Fluoride, 10ul/mL Protease inhibitor cocktail (Fisher Scientific)] and frozen at -20°C. Protein
content was determined using the Micro BCA™ Protein Assay Kit (Thermo Scientific).
Protein (100µg) was reduced in DTT (0.5 M) for 10 minutes at 70°C and samples run on a 415% gradient pre-cast Mini-PROTEAN® TGX™ Gels (Bio-Rad) for 60 minutes at 100V.
Protein molecular weight standards (20-220 kDa) were run simultaneously on each gel.
Electroblotting was performed for 60 minutes at 100V to transfer protein samples to a
nitrocellulose membrane. Blots were blocked in 5% milk in TBS-T for 1 hour, and probed
with an antibody targeting CD63 (1:1,000; Abcam) overnight and washed in TBS-T.
Horseradish peroxidase labelled goat anti-rabbit (1:3,000; Abcam) secondary antibody was
then added to the membranes for 1.5 hours. Following washing steps, SuperSignal West Dura
Chemiluminescent substrate (Thermo Scientific) was applied to the membranes for 5
minutes. Images were captured using a Syngene G-Box and GeneSnap software.

RNA extraction and microRNA array
RNA was extracted from exosomes using the mirVanaTM miRNA isolation kit following
manufacturer’s instructions. The NanodropTM Spectrophotometer (Thermo Scientific) was
used to assess RNA present. Samples extracted from HCT-116 and HT-29 exosomes were
then delivered to Exiqon Services, Denmark. The quality of the total RNA was verified by an
Agilent 2100 Bioanalyzer profile. All RNA from sample and artificial reference was labeled
with Hy3™ and Hy5™ fluorescent label, respectively, using the miRCURY LNA™
microRNA Hi-Power Labelling Kit, Hy3™/Hy5™ (Exiqon, Denmark). The Hy3™-labeled
samples and a Hy5™-labelled reference RNA sample were mixed pair-wise and hybridized
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to the miRCURY LNA™ microRNA Array 7th Gen (Exiqon, Denmark), which contains
capture probes targeting all human microRNAs registered in miRBASE 18.0 [18]. The
hybridization was performed according to the miRCURY LNA™ microRNA Array
Instruction manual. The miRCURY LNA™ microRNA Array slides were scanned using the
Agilent G2565BA Microarray Scanner System (Agilent Technologies, Inc., USA) and image
analysis was carried out using the ImaGene 9.0 software (BioDiscovery, Inc., USA). The
quantified signals were background corrected [19] and normalized using quantile
normalization method. Technical quality assessment was performed based on results from
spike in controls in the array. miRNAs above a certain threshold were considered present.
The background threshold was calculated for each individual microarray slide as 1.2 times
the 25th percentile of the overall signal intensity of the slide. Expression levels were then
calculated on a scale from 0-10 and those with levels less than 4 were deemed undetectable.

Target validation using RQ-PCR
Exosomal miRNAs of interest were reverse transcribed using the MultiScribe™-based HighCapacity cDNA Archive Kit (dNTP 100mM, RT Buffer 10x, RNase Inhibitor 20U/µl, Stem
loop primer 50nM, MultiScribe RT 50U/µl) (Applied Biosystems) and miRNA-specific
primers. The miRNAs were quantified by real-time PCR using TaqMan microRNA kits (Life
Technologies) and the ABI 79000 Fast real-time PCR system (Applied Biosystems) These
reactions were carried out in a final volume of 10 µl comprising of 0.7 µl cDNA, 5 µl
TaqMan® Universal PCR fast Master Mix (2x), 0.5 µl TaqMan® primer-probe mix (0.2µM),
Forward primer (1.5µM), and Reverse Primer (0.7µM) (Applied Biosystems). For target
validation the average cycle threshold at which the selected miRNA appeared is given as the
mean cycle threshold (CT) over 3 separate exosome isolates +/- standard deviation.

Cell transduction
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HCT-116

cells

were

transduced

with

a

miR-379

(mature

sequence:

UGGUAGACUAUGGAACGUAGG; 50nM, HCT-116-379) or a non-specific targeting
control miRNA (non-target control, HCT-116-NTC) mimic (SMARTchoice shMIMIC
Lentiviral microRNAs). Lentiviral vectors contained a red fluorescent protein and Puromycin
resistance element. Transductions were performed using polybrene at a final concentration of
8µg/mL. Puromycin selection was commenced 48 hours after transduction at a concentration
of 8µg/mL. To confirm adequate transduction efficiency cells were fixed in 4%
paraformaldehyde, nuclei were counterstained with DAPI and visualised using a fluorescence
microscope (Olympus BX60, analaSIS® software - Ridom GmbH, Münster, Germany) to
confirm the presence of red fluorescent protein. Confirmation of stable transduction was
performed with RQ-PCR at 1 and 2 weeks. miR-16 was used as the endogenous control.
miR-379 expression was calculated in miR-379 over-expressing versus NTC cells. For every
sample, reactions were performed in triplicate for the miRNA of interest and the endogenous
control miRNA. The relative quantity of mRNA and miRNA expression was calculated using
the comparative cycle threshold (ΔΔCt). The geometric mean of the Ct value was used to
normalise the data and the sample with the lowest expression level was applied as a
calibrator. Following confirmation of transduction, exosomes secreted by HCT-116-379 cells
and HCT-116-NTC were harvested as previously described and miR-379 levels were
assessed using RQ-PCR to determine if miR-379 over-expression was observed in HCT-116379 exosomes establishing engineering of miRNA enriched exosomes.

Proliferation Assays
To assess the effect of miR-379 on cell proliferation, cells were seeded into a 96 well plate at
a density of 1 x 103 cells per well. HCT-116-379 and HCT-116-NTC cells were seeded and
incubated for 24, 48 or 72 hours. At each of these time-points cell proliferation was measured
using a CellTiter 96® AQueousNon-Radioactive Cell proliferation Assay (Promega). To
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establish any functional effect exerted by exosomes secreted by transduced cells exosomes
were isolated from HCT-116-379, HCT-116-NTC and HCT-116-WT cells as previously
described. HCT-116-WT cells were seeded onto a 96 well plate at a density of 1 x 103 per
well and received media containing exosomes from HCT-116-379, HCT-116-NTC or HCT116-WT cells. Proliferation was measured at 48 hours. Each experiment was performed in
triplicate with results expressed against a negative control (cells in exosome depleted media)
as mean +/- SEM. P values were calculated using ANOVA.

Migration Assays
To assess the effect of miR-379 on cell migration, Transwell® Permeable Supports (Corning
Inc, Sigma–Aldrich) with 8.0 μm pores were used to track migration of HCT-116-379 and
HCT-116-NTC cells in response to a chemoattractant (10% FBS). 7.5 x 104 cells were seeded
onto the membranes in serum free media. Migration in response to the same serum free
medium was employed as a negative control. Migrated cells were stained using haematoxylin
and counted in five fields of view per membrane using an Olympus B×60 microscope and
image analysis software. Each experiment was repeated in triplicate, with results expressed
against the negative control as Mean +/- SEM. P values were calculated using Students T test
(two tailed).

Confocal microscopy
Exosomes were isolated from transduced cells expressing a red fluorescent protein. Recipient
WT cells without a red fluorescent protein were seeded onto glass coverslips at a density of 4
x 105 per coverslip. Isolated exosomes were added to coverslips and incubated in a
humidification box for 4 hours. Following incubation cells on coverslips were fixed with 4%
Paraformaldehyde. DNA in cell nuclei was then stained using DAPI (Invitrogen) and the
slides mounted using slowfade gold anti-fade reagent (Invitrogen). Immunofluorescent Z11

stack images (0.1 μm steps) were captured using an Olympus IX81 Microscope fitted with an
Andor Revolution Confocal system (Andor, Belfast, Northern Ireland), 60× oil immersion
objective lens and an EMCCD Andor iXonEM + camera.

RESULTS
Exosome characterisation
Microvesicles with a spherical morphology ranging in size between 40 and 100 nm consistent
with exosomes were found to be secreted by both cell lines and successfully visualised with
TEM (Figure 1A). Western Blot for the exosome-associated protein CD63 revealed a
characteristic band between 50-60 kDa in size (Figure 1B).

Identification of exosomal microRNA content
Expression analysis revealed the number of miRNAs present in the exosomes of both CRC
cell lines to be within the expected range for human samples. 409 miRNAs were detected
above threshold in HT-29 derived exosomes. 393 miRNAs were detected in HCT116
exosomes, with 338 miRNAs common to exosomes from both HCT-116 and HT-29 cells.
The 20 most highly expressed miRNAs in HCT-116 cell secreted exosomes and HT-29 cell
secreted exosomes were identified (Table 1). The miRNAs which were found to have the
highest difference in expression levels between the exosomes secreted by either HCT-116 or
HT-29 cell lines were also identified (Table 2).

Validation of selected array data by qRT-PCR
Selected miRNAs (miR-10b, miR-143 and miR-149-5p) were validated in three separate
exosome isolates from both HCT-116 and HT-29 cell secreted exosomes. miR-10b, miR143
and miR-149-5p were consistently detectable in exosome extracts from both cell lines. miR10b (HCT-116 exosomes 36.25 +/- 0.84 CT, HT-29 exosomes 35 +/- 0.3 CT) , miR-143
12

(HCT-116 exosomes 36.42 +/- 2.42 CT, HT-29 exosomes 35.98 +/- 2.32 CT) and miR-1495p (HCT-116 exosomes 35.41 +/- 1.85 CT, HT-29 exosomes 37.94 +/- 0.34 CT).

miR-379 over-expression in exosomes and functional impact
HCT-116 cells were transduced with a miR-379 and NTC-mimic as described, and the
successfully transduced cells were visualized using fluorescence microscopy (Figure 2A). A
significant elevation in miR-379 expression in HCT-116-379 cells (2.20 log10 RQ increase
relative to HCT-116-NTC) was confirmed at 1 and 2 weeks following transduction (Figure
2B). Proliferation at 24, 48 and 72 hours was determined in HCT-116-379 cells compared to
NTC cells. A significant decrease in proliferation was observed in HCT-116-379 cells
compared to HCT-116-NTC cells (12-15% decrease, ANOVA p < 0.001, Figure 3A). A
significant decrease of up to 86% was observed in HCT-116-379 cell migration towards a
chemo-attractant (10% FBS) when compared to HCT-116-NTC cells (32-86% decrease, p <
0.001, Figure 3B). Exosomes secreted by HCT-116-379 cells contained detectable levels of
miR-379 while those secreted by WT and NTC cells did not.

Transfer of exosomes between cell populations and functional effects
Exosomes with a red fluorescing protein were isolated from miR-379 over-expressing cells.
Recipient WT cell nuclei were stained blue with DAPI. Exosomes isolated from HCT-116379 cells were incubated with HCT-116-WT cells and confocal microscopy visualised
exosomes clustering around HCT-116-WT cells suggesting uptake of miR-379 enriched
exosomes by HCT-116-WT cells (Figure 4A). Proliferation of HCT-116-WT cells in
response to -379, -NTC and -WT secreted exosomes was measured at 48 hours. A trend
towards decreased proliferation of WT cells in response to miR-379 exosomes compared to
NTC and WT exosomes was observed, although this was not significant (Figure 4B).
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DISCUSSION
Dysregulated circulating miRNAs have been identified as promising biomarkers in CRC in
several studies but contradicting evidence exists regarding their reproducibility [9]. Patient
factors, medium from which miRNA is extracted (whole blood/serum/plasma), and differing
collection and storage have led to heterogeneous data. Exosomal miRNAs may provide
tumour specific biomarkers negating these concerns. The profiling of miRNAs secreted
within exosomes by both HCT-116 and HT-29 CRC cells has identified a large number of
miRNAs. Overall, when non-human spike-in miRNAs were excluded, array data revealed
409 miRNAs detected above threshold in HT-29 derived exosomes. 393 miRNAs were
detected in HCT-116 exosomes, with 338 miRNAs common to exosomes from both HCT116 and HT-29 cells. Analysis of miRNA expression levels in both CRC cell secreted
exosomes show areas with distinct differences. The differences between the miRNA profiles
of exosomes secreted by these two distinct CRC cell lines may represent differences in
growth pattern and phenotype [20].

Previous studies have identified selected miRNAs present in exosomes secreted by CRC cells
in vitro [11]. A number of miRNAs have also been identified in exosomes isolated from the
circulation of CRC patients [12]. This is the first study to describe the full range of miRNAs
present in both HCT-116 and HT-29 CRC cell secreted exosomes, demonstrating a large
range of miRNAs some of which have well described roles in cancer pathogenesis, and others
which have only recently been discovered. Among the most highly expressed miRNAs in
both CRC cell line exosomes are several which have previously described roles in
gastrointestinal cancers (miR-10b-3p, let7b-5p, miR-378c, miR-145-5p) [21-24]. In addition,
included in the most highly expressed are some miRNAs with little or no available data
regarding their association with disease states, associated gene targets or functional roles.
These miRNAs may represent new targets as biomarkers worthy of further investigation.
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miR-10b was found to be among the most highly expressed miRNAs in both CRC cell line
exosomes and was validated in multiple exosome samples. High levels of miR-10b have been
associated with a higher incidence of lymphatic invasion and poor prognosis in CRC tissues
[25]. Interestingly, exosome-mediated transfer of miR-10b to recipient non-invasive breast
cancer cell lines has been shown to promote cell invasion in breast cancer [26]. miR-143 and
miR-149-5p were also validated. These miRNAs were not among the most highly expressed
but the fact that they are detectable in multiple exosome isolated from both CRC cell lines
indicates validity of array data.

miR-379 down-regulates several genes involved in the TGF-β signalling pathway and a large
proportion of CRCs are known to display abnormalities in TGF-β pathway factors [27,28]. A
significant reduction in colorectal cancer cell proliferation in response to over-expression of
miR-379 was observed. Cells over expressing miR-379 were found to proliferate between 1215% slower compared to controls. A marked reduction in migration of CRC cells in response
to over-expression of miR-379 was observed ranging as high as an 86%. This effect is
interesting as miR-379 has a documented effect on cyclin B1. Cyclin B1 in turn has a
documented inhibitory effect on E-cadherin leading to induction of CRC cell migration and
invasion which is contrary to the effect observed in this study and worthy of further
investigation [28]. Exosomes which were secreted from miR-379 over-expressing cells were
found to contain detectable levels of miR-379 compared to exosomes secreted by HCT-116NTC and HCT-116-WT cells. In addition, miR-379 was not detected through miRNA array
performed on HCT-116-WT exosomes. Incubation of HCT-116-WT cells in media
containing exosomes enriched in miR-379 produced an observable decrease in proliferation
however it was not significant. As the effect of miR-379 over-expression on migration was
very significant, ranging from 32-86%, further investigation of the effect of miR-379
enriched exosomes on cell migration may yield a more pronounced effect.
15

The data presented identifies a wide range of miRNAs present in CRC cell secreted exosomes
which may provide useful targets as biomarkers for further investigation. miR-379 displays
tumour suppressor properties in CRC cells and its potential to be delivered to recipient cells
warrants further investigation.
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Figure and Table Legends
Figure 1
Title: Characterisation of exosomes isolated from HCT-116 and HT-29 colorectal cancer cell
lines.
A) Transmission electron microscopy images of exosomes from HCT-116 and HT-29
CRC cells (bar = 500nm)
B) Western Blot for exosome associated protein CD63 performed with protein extracted
from both HCT-116 and HT-29 CRC cell lines.

Figure 2
Title: Confirmation of transduction forcing miR-379 over-expression in HCT-116-379 CRC
cells
A) Visualisation of transduced cells with fluorescence microscopy. (i) - Cell nuclei
stained blue with DAPI. (ii) – Red Fluorescent Protein of successfully transduced cells
B) Elevated miR-379 expression in HCT-116-379 cells 1 and 2 weeks following
transduction

Figure 3
Title: Analysis of functional effects of miR-379 over-expression
A) Cell proliferation following transduction resulting in a decrease in proliferation (range
12-15%) in the presence of miR-379 over-expression (p<0.001)
B) Cell migration following transduction resulting in a decrease in migration (range 32
86% decrease) in the presence of miR-379 over-expression (p<0.001)
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Figure 4
Title: Exosome transfer and functional effect on recipient cells
A) Confocal microscopy image of exosomes isolated from miR-379 over expressing
cells (red due to RFP labelling) clustering around WT cells (blue DAPI stained
nuclei).
B) Functional effects of exosomes isolated from HCT-116-WT, HCT-116-NTC and
HCT-116-379 cells on recipient WT cells.

Table 1
Title: The 20 most highly expressed miRNAs in HCT-116 and HT-29 cell secreted exosomes.
(Complete dataset available at www.microvesicles.org. Experiment ID – Vesiclepedia_557)
[29]

Table 2
Title: The 10 most differentially expressed miRNAs contained within exosomes secreted by
both cell lines (the miRNAs with the most significant difference in expression in one cell line
compared to another)
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Table 1
Most highly expressed
microRNAs in
HCT-116 exosomes
hsa-miR-3679-3p
hsa-miR-4279
hsa-miR-642b-5p
hsa-miR-4454
hsa-miR-10b-3p
hsa-miR-624-5p
hsa-miR-943
hsa-miR-4723-3p
hsa-miR-1249
hsa-miR-378c
hsa-miR-1248
hsa-miR-718
hsa-let-7b-5p
hsa-miR-1246
hsa-miR-4274
hsa-miR-1207-3p
hsa-miR-4728-3p
hsa-miR-365a/b-3p
hsa-miR-30d-3p
hsa-miR-3679-3p
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Most highly expressed
microRNAs in HT-29
exosomes
hsa-miR-642b-5p
hsa-miR-10b-3p
hsa-miR-3679-3p
hsa-miR-4279
hsa-miR-943
hsa-miR-624-5p
hsa-miR-1248
hsa-miR-145-5p
hsa-miR-1249
hsa-miR-4723-3p
hsa-let-7b-5p
hsa-miR-378c
hsa-miR-365a/b-3p
hsa-miR-30d-3p
hsa-miR-4274
hsa-miR-718
hsa-miR-548k
hsa-miR-361-5p
hsa-miR-1207-3p
hsa-miR-4311

Table 2
HCT-116 cell secreted exosomes
Differentially expressed
microRNAs
miR-4497
miR-377-5p
miR-3960
miR-670-5p
miR-4787-5p
miR-1246
miR-5100
miR-4454
miR-1260b
miR-4708-3p
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HT-29 cell secreted exosomes
Differentially expressed
microRNAs
miR-1250-5p
miR-511-5p
miR-1224-3p
miR-29c-5p
miR-3144-3p
miR-513c-5p
miR-25-3p
miR-192-3p
miR-1225-5p
miR-1304-5p
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